1[1]Forrester JS.Role of plague rupture in acute coronary syndrome.Am J Cardiol,2000,86(8B):15-23
2[2]Han DK,Haudenschild CC,Bortier HE,et al.Evidence for apoptosis in human atherogenesis and in a rat vascular injury model.Am J Pathol,1995,147(2):267-277
3[3]Bochaton-Piallat ML,Gabbiani F,Redard M,et al.Apoptosis participates in cellularity regulation during rat aortic intimal thickening.Am J Pathol,1995,146(5):1059-1064
4[4]Huang YH,Ronnelid J,Frostegard J.Oxidized LDL induces enhanced antibody formation and MHC class-dependent IFN-gamma production lymphocytes from healthy individuals.Arterioscler Thromb Vasc Biol,1995,15(10):1577-1583
5Alpert J S, Thygesen K, Antman E, et al. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol , 2000,36:959.
6Feruson JL, Beckett GJ, Stoddart M, et al. Myocardial infarction redefined: the new ACC/ESC definition, based on cardiac troportia, increases the apparent incidence of infarction. Heart,2002,88(4) :343.
7Meier MA, Albar WH, Cooper JV, et al. The new definition of myocardial infarction : diagnostic and prognostic implications in patients with acute coronary syndromes. Arch Intern Med, 2002,162(14): 1585.
8Sousa E, Costa MA, Sousa A, et al. Two- year angiographic and intravascular ultrasound follow- up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation, 2003,107:381.
9Grube E , Silber S, Eugen HK, et al. Six- and twelve- month results from a randomized, double- blind trial on a slow- release paclitaxel - eluting stent for de novo coronary lesions. Circulation,2003,107 : 38.
10Braunwald E, Antman EM, Califf RM, et al. Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation, 2002, 106:1893.
2Mukherjee D,Sen S.Alteration of collagen phenotypes in ischemic cardiomyopathy[J].J Clin Invest,1991,88:1141-1146.
3Tyagi SC,Kumar SG,Hass SJ,et al.Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy[J].J Mol Cell Cardiol,1996,28:1415-1428.
4Schwartzkoff B,Michael M,Pelzer B,et al.Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy[J].Eur J Heart Fail,2002,4:439-444.
5Lombardi R,Betocchi S,Losi MA,et al.Myocardial collagen turnover in hypertrophic cardiomyopathy[J].Circulation,2003,108:1455-1460.
6Blankenberg S,Rupprecht HJ,Poirier O,et al.Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease[J].Circulation,2003,107:1579-1585.
7Spinal FG,Coker MJ,Heung LJ,et al.A matrix metalloprotionase indution/activation system exists in the human left ventricular myocardium and is upregulated in heart failure[J].Circulation,2000,102:1944-1949.
8Hein S,Schaper J.The extracellular matrix in normal and diseased myocardium[J].J Nul Cardio1,2001,8:188-196.
9Lindsay M,Maxwell P,Dunn FG.TIMP-1 a marker of left ventricular diastolic dysfunction and fibrosis in hypertension[J].Hypertension,2002,40:136-141.
10Nagase H,Visse R.Matrix metalloproteinase and tissue inhibitors:structure,function,and biochemistry[J].Circ Res,2003,92:827-839.
